期刊文献+

HPLC法测定人血浆中瑞格列奈浓度 被引量:5

Determination of Repaglinide Concentration in Human Plasma by HPLC
下载PDF
导出
摘要 目的:以往测定人血浆中瑞格列奈多采用LC-MS法和LC-MS/MS法,方法灵敏度高,但是由于试验成本较高无法普及,故研究建立人血浆中瑞格列奈浓度测定的HPLC方法。方法:采用高效液相色谱法,色谱柱为Agilent Zorbax C18柱(150mm×4.6mm,5μm),流动相为乙腈-醋酸铵缓冲液(10mmol/mL,pH4.0)(78:22,V/V);流速1mL/min,检测波长245nm,柱温34℃,进样量20μL。结果:血浆中杂质不干扰样品的测定;瑞格列奈血药浓度在2.0~100ng/mL范围内线性关系良好,定量下限为2.0ng/mL;高、中、低3种浓度的日内、日间RSD均〈10%;绝对回收率为83.8%~93.2%,相对回收率92.7%~105.3%。结论:本方法快速、简便、重现性好,可用于瑞格列奈的临床药动学和药效学研究。 Objective: Separation of repaglinide by LC-MS or LC-MS/MS has the advantage of high sensitivity, but its utility is limited for its expensive cost. The method for determination of repaglinide concentration in human plasma by HPLC was established. Method: Separation was performed on Agilent Zorbax C 18(150mm × 4.6 mm, 5mm) column with a mobile phase consisted of acetonitrile and ammonium acetate buffer (10mmol/L, pH4.0) (78:22, V/V) at the conditions of below: flow rate 1 mL/min, column temperature 34℃, detection wavelength 245 nm and injection volume 20 μ L. Results: The linear range of repaglinide was 2.0-100.0ng/mL, and the lower determination limit was 2.0ng/mL. RSDs of intra-day and inter-day were all less than 10%. Absolute recovery was 83.8%-93.2% and relative recovery was 92.7%-105.3%. Conclusion: Our method is rapid, convenient, sensitive and reproducible for clinical pharmacokinetic and pharmacodynamic study of repaglinide.
作者 张倩 朱余兵
出处 《药品评价》 CAS 2013年第12期31-33,共3页 Drug Evaluation
基金 "瑞格列奈治疗的Ⅱ型糖尿病患者血药浓度与药效学相关性研究" 2011紫禁城国际药师论坛科研基金资助项目 编号:zjc2011005 "单独应用瑞格列奈治疗的2型糖尿病患者体内血药浓度与药效学相关性研究" 2011南京医科大学科技发展基金面上项目 编号:2011NJMU022
关键词 瑞格列奈 高效液相色谱法 血药浓度 Repaglinide HPLC Plasma Concentration
  • 相关文献

参考文献6

二级参考文献30

  • 1谭志荣,欧阳冬生,韩春婷,周淦,陈尧,曾玲,郭栋,郑姣,韩仰,彭亮,王连生,李智,王丹,胡东莉,周宏灏.那格列奈胶囊和片剂的人体药物动力学及生物等效性研究[J].中南药学,2006,4(5):343-345. 被引量:7
  • 2姚静,张启明,李卓荣,金少鸿.高效液相色谱法测定瑞格列奈片的含量[J].药物分析杂志,2007,27(5):728-729. 被引量:7
  • 3韩书宏,邱健青,黄镇,陈亚想.瑞格列奈治疗2型糖尿病的临床疗效[J].中国医药导报,2007,4(06S):53-54. 被引量:15
  • 4Vibeke Hatorp, MS Pharm. Repaglinide Pharmaeokinetics in Healthy Young Adult and Elderly Subjects [J]. Clinical Therapeutics, 1999, 21 (4): 702-710.
  • 5Schmacher S. , Ahbasi I, Weise D, et al. Single-and multipledose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment [J]. Eur J Clin Pharmacol, 2001, 57 (2): 147-152.
  • 6A Kalliokoski, JT Backman, KJ Kurkinen, et al. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism[J]. Clinical pharmacology & Therapeutics, 2008, 84 (4): 488-496.
  • 7M. Niemi, J. T. Backman, M. Neuvonen. Rifampin decrease the plasma concentrations and effect of repaglinide [J] Clin. Pharmacol. Ther, 2000, 68 (5): 495-500.
  • 8Schmacher S, Abbasi I, Weise D, et ',d. Single-and multiple-dose pharmaeokineties of repaglinide in patients with type 2 diabetes and renal impairment[J]. Eur J Clin Pharmacol, 2001,57(2) : 147 - 152.
  • 9Ruzilawati AB, Wahab MS, Imran A, et al. Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies [J]. J Pharm Biomed Anal, 2007,43(5) : 1831 - 1835.
  • 10Kalliokoski A, Backman JT, Kurkinen KJ, et al. Effects of gemfibrozil and atorvastatin on the phannacokinetics of repaglinide in relation to SLCO1B1 polymorphism[J]. Clin Pharmacol Ther, 2008,84(4) :488 - 496.

共引文献24

同被引文献33

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部